Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy

American Journal of Pathology

Volumn 178, Issue 6, 2011, Pages 2573-2586

  Lu, Ailing ^a   Miao, Mi ^a   Schoeb, Trenton R ^b   Agarwal, Anupam ^c   Murphy Ullrich, Joanne E ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; FIBRONECTIN; LEUCINE SERINE LYSINE LEUCINE; NEPHRIN; RECOMBINANT PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AKITA MOUSE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME ACTIVITY; GLOMERULOSCLEROSIS; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY INJURY; MALE; MOUSE; MOUSE STRAIN; NEPHRECTOMY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; SYSTEMATIC REVIEW; WOUND HEALING; [LEUCINE SERINE LYSINE LEUCINE;

EID: 79959473807     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.02.039     Document Type: Article

References (76)

1. Ziyadeh FN: Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 2004, 15(Suppl 1):S55-S57 (Pubitemid 38018457)
2. Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999, 34:795-808 (Pubitemid 29521694)
3. Tsuchida K, Cronin B, Sharma K: Novel aspects of transforming growth factor-β in diabetic kidney disease. Nephron 2002, 92:7-21 (Pubitemid 34983870)
4. Wolf G: Growth factors and the development of diabetic nephropathy. Curr Diab Rep 2003, 3:485-490 (Pubitemid 38906809)
5. Ziyadeh FN, Wolf G: Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008, 4:39-45 (Pubitemid 351210971)
6. Hoffman BB, Sharma K, Zhu Y, Ziyadeh FN: Transcriptional activation of transforming growth factor-β1 in mesangial cell culture by high glucose concentration. Kidney Int 1998, 54:1107-1116 (Pubitemid 28449897)
7. Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE: Glucose stimulation of transforming growth factor-β bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol 2000, 157:1353-1363
8. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger EP: Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest 2001, 108:807-816 (Pubitemid 32880291)
9. Li Y, Kang YS, Dai C, Kiss LP, Wen X, Liu Y: Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008, 172:299-308 (Pubitemid 351282018)
10. van den Heuvel M, Batenburg WW, Danser AH: Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF-β1 axis? Mol Cell Endocrinol 2009, 302:213-218
11. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB, Weisberg LS: Increased renal production of transforming growth factor-β1 in patients with type II diabetes. Diabetes 1997, 46:854-859 (Pubitemid 27188264)
12. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015-8020 (Pubitemid 30460765)
13. Shankland SJ, Scholey JW, Ly H, Thai K: Expression of transforming growth factor-β 1 during diabetic renal hypertrophy. Kidney Int 1994, 46:430-442 (Pubitemid 24253050)
14. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S, Remuzzi G: Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003, 14:1816-1824 (Pubitemid 36750476)
15. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45:522-530
16. Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 1994, 266:F829-F842
17. Shah IM, Mackay SP, McKay GA: Therapeutic strategies in the treatment of diabetic nephropathy: a translational medicine approach. Curr Med Chem 2009, 16:997-1016
18. Markowitz SD, Roberts AB: Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 1996, 7:93-102 (Pubitemid 27202668)
19. Letterio JJ, Roberts AB: Regulation of immune responses by TGF-β. Annu Rev Immunol 1998, 16:137-161
20. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB: Latent transforming growth factor-β: structural features and mechanisms of activation. Kidney Int 1997, 51:1376-1382 (Pubitemid 27239886)
21. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D: The integrin αvβ6 binds and activates latent TGF β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999, 96:319-328 (Pubitemid 29077586)
22. Barcellos-Hoff MH, Dix TA: Redox-mediated activation of latent transforming growth factor-β1. Mol Endocrinol 1996, 10:1077-1083 (Pubitemid 26299216)
23. Wipff PJ, Rifkin DB, Meister JJ, Hinz B: Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J Cell Biol 2007, 179:1311-1323 (Pubitemid 350277747)
24. Ahamed J, Janczak CA, Wittkowski KM, Coller BS: In vitro and in vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring- and shear-dependent activation of platelet-derived TGF-β1. PLoS One 2009, 4:e6608
25. Schultz-Cherry S, Murphy-Ullrich JE: Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 1993, 122:923-932 (Pubitemid 23241101)
26. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N: Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 1998, 93:1159-1170 (Pubitemid 28307421)
27. Young GD, Murphy-Ullrich JE: Molecular interactions that confer latency to transforming growth factor-β. J Biol Chem 2004, 279:38032-38039 (Pubitemid 39195519)
28. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE: Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin. J Biol Chem 1995, 270:7304-7310
29. Murphy-Ullrich JE, Poczatek M: Activation of latent TGF-β by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000, 11:59-69 (Pubitemid 30169726)
30. Wang S, Shiva S, Poczatek MH, Darley-Usmar V, Murphy-Ullrich JE: Nitric oxide and cGMP-dependent protein kinase regulation of glucose- mediated thrombospondin 1-dependent transforming growth factor-β activation in mesangial cells. J Biol Chem 2002, 277:9880-9888 (Pubitemid 34968093)
31. Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE: Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-β activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem 2004, 279:34311-34322 (Pubitemid 39318055)
32. Han SH, Yang S, Jung DS, Li JJ, Kim JJ, Kwak SJ, Kim DK, Moon SJ, Lee JE, Han DS, Kang SW: Gene expression patterns in glucosestimulated podocytes. Biochem Biophys Res Commun 2008, 370: 514-518
33. Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE: Thrombospondin 1 mediates angiotensin II induction of TGF-β activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun 2006, 339:633-641 (Pubitemid 41739714)
34. Hohenstein B, Daniel C, Hausknecht B, Boehmer K, Riess R, Amann KU, Hugo CP: Correlation of enhanced thrombospondin-1 expression: TGF-β signalling and proteinuria in human type-2 diabetic nephropathy, Nephrol Dial Transplant 2008, 23:3880-3887
35. Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babelova A, Schaefer R, Mason RM: Glomerular expression of thrombospondin-1, transforming growth factor β and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 2005, 48:2650-2660 (Pubitemid 41738234)
36. Daniel C, Schaub K, Amann K, Lawler J, Hugo C: Thrombospondin-1 is an endogenous activator of TGF-β in experimental diabetic nephropathy in vivo. Diabetes 2007, 56:2982-2989 (Pubitemid 350223633)
37. Liu S, Shi L, Wang S: Overexpression of upstream stimulatory factor 2 accelerates diabetic kidney injury. Am J Physiol Renal Physiol 2007, 293:F1727-F1735 (Pubitemid 350086009)
38. Yang YL, Chuang LY, Guh JY, Liu SF, Hung MY, Liao TN, Huang YL: Thrombospondin-1 mediates distal tubule hypertrophy induced by glycated albumin. Biochem J 2004, 379:89-97
39. Belmadani S, Bernal J, Wei CC, Pallero MA, Dell'italia L, Murphy- Ullrich JE, Berecek KH: A thrombospondin-1 antagonist of transforming growth factor-β activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am J Pathol 2007, 171:777-789 (Pubitemid 47440977)
40. Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD: Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005, 54:2628-2637 (Pubitemid 41233584)
41. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM: Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 2006, 290:F214-F222
42. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB: An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994, 216:276-284 (Pubitemid 24076008)
43. Takahashi N, Boysen G, Li F, Li Y, Swenberg JA: Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int 2007, 71:266-271 (Pubitemid 46160928)
44. Sullivan SR, Underwood RA, Gibran NS, Sigle RO, Usui ML, Carter WG, Olerud JE: Validation of a model for the study of multiple wounds in the diabetic mouse (db/db). Plast Reconstr Surg 2004, 113:953-960 (Pubitemid 39195758)
45. Yoshioka M, Kayo T, Ikeda T, Koizumi A: A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997, 46:887-894 (Pubitemid 27188269)
46. Levine DZ, Iacovitti M, Robertson SJ: Modulation of single-nephron GFR in the db/db mouse model of type 2 diabetes mellitus, II: effects of renal mass reduction. Am J Physiol Regul Integr Comp Physiol 2008, 294:R1840-R1846
47. Tryggvason K: Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 1999, 10:2440-2445 (Pubitemid 29501479)
48. Hugo C, Shankland SJ, Pichler RH, Couser WG, Johnson RJ: Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int 1998, 53: 302-311 (Pubitemid 28097847)
49. Dixon AJ, Burns J, Dunnill MS, McGee JO: Distribution of fibronectin in normal and diseased human kidneys. J Clin Pathol 1980, 33:1021-1028 (Pubitemid 11194193)
50. Tada H, Isogai S: The fibronectin production is increased by thrombospondin via activation of TGF-β in cultured human mesangial cells. Nephron 1998, 79:38-43 (Pubitemid 28204036)
51. Lee PY, Chesnoy S, Huang L: Electroporatic delivery of TGF-β1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol 2004, 123:791-798 (Pubitemid 39281623)
52. Chesnoy S, Lee PY, Huang L: Intradermal injection of transforming growth factor-β1 gene enhances wound healing in genetically diabetic mice. Pharm Res 2003, 20:345-350 (Pubitemid 36288362)
53. Kosugi T, Heinig M, Nakayama T, Connor T, Yuzawa Y, Li Q, Hauswirth WW, Grant MB, Croker BP, Campbell-Thompson M, Zhang L, Atkinson MA, Segal MS, Nakagawa T: Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. Am J Pathol 2009, 174: 1221-1229
54. Yevdokimova N, Wahab NA, Mason RM: Thrombospondin-1 is the key activator of TGF-β1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol 2001, 12:703-712 (Pubitemid 32246698)
55. Daniel C, Wiede J, Krutzsch HC, Ribeiro SM, Roberts DD, Murphy- Ullrich JE, Hugo C: Thrombospondin-1 is a major activator of TGF-β in fibrotic renal disease in the rat in vivo. Kidney Int 2004, 65:459-468 (Pubitemid 38130640)
56. Olson BA, Day JR, Laping NJ: Age-related expression of renal thrombospondin 1 mRNA in F344 rats: resemblance to diabetes-induced expression in obese Zucker rats. Pharmacology 1999, 58:200-208 (Pubitemid 29118884)
57. Hohenstein B, Daniel C, Hausknecht B, Boehmer K, Riess R, Amann KU, Hugo CP: Correlation of enhanced thrombospondin-1 expression, TGF-β signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant 2008, 23:3880-3887
58. Yung S, Lee CY, Zhang Q, Lau SK, Tsang RC, Chan TM: Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-β1 dependent and TGF-β1 independent pathways. Nephrol Dial Transplant 2006, 21:1504-1513 (Pubitemid 44063124)
59. Yang YL, Lin SH, Chuang LY, Guh JY, Liao TN, Lee TC, Chang WT, Chang FR, Hung MY, Chiang TA, Hung CY: CD36 is a novel and potential anti-fibrogenic target in albumin-induced renal proximal tubule fibrosis. J Cell Biochem 2007, 101:735-744
60. Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992, 20:1-17
61. Benigni A, Zoja C, Campana M, Corna D, Sangalli F, Rottoli D, Gagliardini E, Conti S, Ledbetter S, Remuzzi G: Beneficial effect of TGFβ antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol 2006, 104:e158-e168 (Pubitemid 44885063)
62. Parving HH: Diabetic nephropathy: prevention and treatment. Kidney Int 2001, 60:2041-2055
63. Sharma R, Khanna A, Sharma M, Savin VJ: Transforming growth factor-β1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int 2000, 58:131-136 (Pubitemid 30429857)
64. Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, Zanchi C, Longaretti L, Donadelli R, Remuzzi G: Transforming growth factor-β1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002, 161:2179-2193 (Pubitemid 35434863)
65. Meek RL, Cooney SK, Flynn SD, Chouinard RF, Poczatek MH, Murphy- Ullrich JE, Tuttle KR: Amino acids induce indicators of response to injury in glomerular mesangial cells. Am J Physiol Renal Physiol 2003, 285:F79-F86 (Pubitemid 36818464)
66. Gurley SB, Mach CL, Stegbauer J, Yang J, Snow KP, Hu A, Meyer TW, Coffman TM: Influence of genetic background on albuminuria and kidney injury in Ins2(+/C96Y) (Akita) mice. Am J Physiol Renal Physiol 298:F788-F795
67. Dahly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ: Antihypertensive effects of chronic anti-TGF-β antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 2002, 283:R757-R767 (Pubitemid 34951629)
68. Blakytny R, Jude E: The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 2006, 23:594-608 (Pubitemid 43830059)
69. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL: Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003, 90:133-146 (Pubitemid 36237887)
70. Benn SI, Whitsitt JS, Broadley KN, Nanney LB, Perkins D, He L, Patel M, Morgan JR, Swain WF, Davidson JM: Particle-mediated gene transfer with transforming growth factor-β1 cDNAs enhances wound repair in rat skin. J Clin Invest 1996, 98:2894-2902 (Pubitemid 26427419)
71. Yevdokimova NY: High glucose-induced alterations of extracellular matrix of human skin fibroblasts are not dependent on TSP-1-TGFβ1 pathway. J Diabetes Complications 2003, 17:355-364 (Pubitemid 37315946)
72. Sakai K, Sumi Y, Muramatsu H, Hata K, Muramatsu T, Ueda M: Thrombospondin-1 promotes fibroblast-mediated collagen gel contraction caused by activation of latent transforming growth factor β-1. J Dermatol Sci 2003, 31:99-109 (Pubitemid 36379060)
73. Agah A, Kyriakides TR, Lawler J, Bornstein P: The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double- TSP1/TSP2-null mice. Am J Pathol 2002, 161:831-839 (Pubitemid 34988370)
74. Nor JE, DiPiertro L, Murphy-Ullrich JE, Hynes RO, Lawler J, Polverini PJ: Activation of latent TGF-β by thrombospondin-1 is a major component of wound repair. Oral Biosci Med 2005, 2:153-161
75. Yang K, Vega JL, Hadzipasic M, Schatzmann Peron JP, Zhu B, Carrier Y, Masli S, Rizzo LV, Weiner HL: Deficiency of thrombospondin-1reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2009, 32:94-103
76. Oida TZX, Goto M, Hachimura S, Totsuka M, Kaminogawa S, Weiner HL: CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4CD45 RB high-induced colitis by a TGF-β- dependent mechanism. J Immunol 2003, 170:2516-2522 (Pubitemid 36245641)